PRECISION ONCOLOGY PLATFORM

Every patient with cancer deserves complete answers

Because no two cancers are the same, we go beyond limited testing to uncover the full genomic profile of each patient’s disease, bringing clarity to complex decisions and helping guide more personalized care.

Start with the insight you need:

Patients

Physicians

Biopharma Partners

The Power Behind Precision Oncology

1 Million+

Cases

400,000

Human Life Years
Added in 2025

23,000+

Genes

6.5 Million+

Tests Completed

PRECISION ONCOLOGY ECOSYSTEM

How Patients, Physicians and Biopharma connect through Caris

Building upon industry-leading comprehensive molecular profiling in tissue and blood, Caris not only connects patients with therapies and clinical trials, but also connects drug developers with an experienced profiling laboratory infrastructure to support discovery, clinical development, translational medicine and commercialization.

Explore Solutions

PRECISION ONCOLOGY ECOSYSTEM

How Patients, Physicians, and Biopharma connect through Caris

Building upon industry-leading, comprehensive molecular profiling in tissue and blood, Caris not only connects patients with therapies and clinical trials, but also connects drug developers with an experienced profiling laboratory infrastructure to support discovery, clinical development, translational medicine and commercialization.

Explore Solutions

FOUNDED in 2008

Caris is a pioneer and industry leader in molecular profiling with the data and outcomes to prove it.

By combining and analyzing massive amounts of genomic, transcriptomic and proteomic data, Caris has created one of the largest, most comprehensive multimodal databases of molecular and clinical outcomes data in the world. This wealth of information – and the insights it unlocks – provides the foundation for our ability to deliver on the promise of precision medicine.

COMPREHENSIVE PROFILING SOLUTIONS

Bringing the Future of Personalized Medicine to Cancer Patients Today

Caris molecular profiling options guide more precise and individualized treatment decisions for cancer patients. Caris molecular profiling platforms examine over 23,000 DNA and RNA genes by Whole Exome (WES) and Whole Transcriptome Sequencing (WTS), whether analyzing tissue or blood.

Tumor Tissue Sample

MI Cancer Seek®

Comprehensive molecular insights that help clarify diagnosis, guide treatment decisions, and support better outcomes for patients.

The first and only simultaneous WES/WTS-based assay with CDx indications for adult and pediatric patients (ages 1+).

Tumor Tissue Sample

MI Clarity

AI-powered prognostic test for HR+/HER2- early-stage breast cancer.

Analyzes digitized H&E whole slide images combined with clinical inputs to stratify patients into low- and high-risk categories for both early (Years 0–5) and late (Years 5–15) distant recurrence

Blood Sample

Caris Assure®

Whole Blood. Whole Picture.

Caris Assure is the only liquid biopsy that analyzes both plasma and buffy coat variants, providing a more complete molecular profile.

Blood / Bone Marrow

Caris ChromoSeq™

Comprehensive genomic analysis for myeloid malignancies designed to replace conventional karyotyping, FISH, and NGS workflows.

Myeloid malignancies are complex. Genetic testing shouldn’t be. Caris ChromoSeqTM, a whole-genome sequencing assay, brings the complete molecular picture into a single test, supporting more confident diagnosis, risk stratification, and treatment decisions in myeloid malignancies.

Tumor Tissue Sample

MI Profile

Comprehensive molecular profiling that helps guide precise and individualized treatment decisions.

Assessment of DNA, RNA and Proteins from tumor tissue to reveal a more complete molecular blueprint for clinicians to assess next steps forward in a patient’s care.

Available globally
*Excluding United States of America, EEA, EU and CH countries

Tumor Tissue Sample

MI Tumor Seek Hybrid

One assay that provides a comprehensive molecular blueprint that saves tissue without compromising results.

A laboratory developed test (LDT) that simultaneously captures both DNA and RNA in one assay. Results also include AI signatures to help confirm diagnosis and improve therapy selection.

Available globally
*Excluding United States of America, EEA, EU and CH countries

“Caris was built for one reason—to improve the human condition.

Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work—the patient.”

David Dean Halbert, DSc (h.c.)
Chairman, Founder and CEO

More About Caris